<DOC>
	<DOCNO>NCT00305838</DOCNO>
	<brief_summary>RATIONALE : Estrogen may cause growth ovarian cancer cell . Hormone therapy use tamoxifen may fight ovarian cancer block use estrogen tumor cell . Measuring CA 125 level may help doctor predict patient 's response tamoxifen help plan best treatment . PURPOSE : This phase II trial study CA 125 level treat patient relapse advanced ovarian cancer , fallopian tube cancer , primary peritoneal cancer receive tamoxifen .</brief_summary>
	<brief_title>CA 125 Levels Treating Patients With Relapsed Advanced Ovarian Cancer , Fallopian Tube Cancer , Primary Peritoneal Cancer Who Are Receiving Tamoxifen</brief_title>
	<detailed_description>OBJECTIVES : - Determine percentage patient relapse advanced ovarian carcinoma , fallopian tube carcinoma , primary peritoneal carcinoma log linear rise CA 125 level . - Determine whether log linear part curve consistent enough allow comparison slope introduction new therapy . - Compare serial doubling time commence tamoxifen citrate treatment . - Determine number patient require detect significant difference CA 125 double time start tamoxifen citrate treatment . OUTLINE : Patients undergo blood collection month measure CA 125 level . Once CA 125 level go upper limit normal ( ULN ) start rise nadir level ( previously normal ) , CA 125 level measure every 2 week . When CA 125 level reach 4 time ULN 4 time nadir level ( previously normal ) , patient begin oral tamoxifen citrate daily 3-6 month absence disease progression unacceptable toxicity . CA 125 level continue measure every 2 week treatment . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced ovarian carcinoma , fallopian tube carcinoma , primary peritoneal carcinoma Completed therapy first relapse Had elevate CA 125 level start relapse therapy â‰¥ 50 % fall completion therapy response accord RECIST criterion No significant cancerrelated symptom require urgent treatment PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month Hemoglobin &gt; 10 g/dL WBC &gt; 2,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine &lt; 2 time upper limit normal ( ULN ) AST/ALT &lt; 2 time ULN Bilirubin &lt; 1.5 time ULN No evidence significant clinical disorder laboratory find would preclude study participation No psychiatric disorder would preclude informed consent Not pregnant nursing PRIOR CONCURRENT THERAPY : No concurrent hormonal therapy , except hormonereplacement therapy Other concurrent medication allow provide dose stable</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>recurrent fallopian tube cancer</keyword>
	<keyword>stage IIIA fallopian tube cancer</keyword>
	<keyword>stage IIIB fallopian tube cancer</keyword>
	<keyword>stage IIIC fallopian tube cancer</keyword>
	<keyword>stage IV fallopian tube cancer</keyword>
	<keyword>recurrent primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIA primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIB primary peritoneal cavity cancer</keyword>
	<keyword>stage IIIC primary peritoneal cavity cancer</keyword>
	<keyword>stage IV primary peritoneal cavity cancer</keyword>
</DOC>